Latest News

Future uncertain for active immunotherapies in AD – Part 1

 

View Part II

The recent failure of active immunotherapies targeting beta-amyloid in Alzheimer’s disease has dampened some of the initial enthusiasm for this approach. Development of AN1792, an active beta-amyloid vaccine, was terminated following the development of meningoencephalitis in 6% of vaccinated subjects. This complication was attributed to use of full-length beta-amyloid1-42. Read More

TOPICS:

NeuroSound Radio at ACTRIMS/ECTRIMS 2014 – Part 1

 

Dr. Marcelo Kremenchutzky, Director of the MS Clinic in London, Ontario, interviews researchers and clinicians at MSBoston 2014, the joint meeting of the Americas and European Committee for Treatment and Research in MS (ACTRIMS/ECTRIMS). Read More